Wegovy vs Mounjaro Side Effects: Are They Really Different?

The decision most people are really making

You probably landed here because you've heard one medicine is "harder on the stomach" than the other, or a friend swore off Mounjaro after a miserable first month and switched to Wegovy (or vice versa). That's a genuinely common situation. The frustrating truth is that GI tolerance is personal, the person next to you on the same dose of the same medicine may barely notice a thing while you're cancelling plans. What the clinical data can tell us is how the two drugs' side-effect patterns differ on average, and where the biology gives a clue about why.

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) slow gastric emptying and suppress appetite through gut-hormone pathways. Wegovy activates one receptor, GLP-1. Mounjaro activates two, GLP-1 and GIP. That dual mechanism is why Mounjaro tends to produce greater average weight loss, but it also means the two medicines interact with your gut slightly differently. Our full Wegovy vs Mounjaro comparison covers efficacy alongside the safety picture; this page focuses purely on how symptoms differ.

The table below draws on the NHS medicines pages and the licensed product information for both medicines. A detailed breakdown of side effects by medicine has more on individual symptom frequency.

Sources: NHS tirzepatide medicines page; NHS semaglutide medicines page.

Where the differences actually show up

The headline categories look almost identical (nausea, vomiting, diarrhoea, constipation, indigestion) which is why this comparison is so difficult to resolve in a sentence. The differences that matter tend to be in timing and individual response rather than in which symptoms appear.

In the STEP 1 trial (semaglutide 2.4mg, 68 weeks), GI events were the most common reason for discontinuation. The SURMOUNT-1 trial (tirzepatide, 72 weeks) showed a broadly similar pattern. Participants on the higher doses of either medicine reported more symptoms than those on lower doses, which makes sense given that side effects are often most noticeable after a dose increase and tend to settle over a week or two as the body adjusts. Neither trial was designed as a head-to-head on tolerability, so direct frequency comparisons carry uncertainty. The question of which medicine causes more side effects does not have a clean evidence-based winner.

One practical distinction: some people find constipation slightly more prominent on tirzepatide, while others report that nausea fades faster on it than on semaglutide. These are patient-level observations, not trial findings, and they're worth raising with a prescriber rather than using to self-select a medicine. If you want to read more about the symptom-by-symptom comparison, this page compares the profiles in more depth.

The contraceptive pill: a real and often missed difference

This is the one area where the two medicines diverge clearly. NHS guidance states that women taking the oral contraceptive pill should use an additional non-oral method (such as condoms) for the first four weeks of Mounjaro treatment, and for four weeks after each dose increase. The reason is straightforward: by slowing gastric emptying, tirzepatide may reduce how much of an oral medicine is absorbed. The same concern applies in principle to any oral drug that depends on gut absorption, which is why your prescriber needs to know everything you're taking.

There is no equivalent NHS warning for semaglutide. That doesn't mean semaglutide has no effect on absorption (it also slows gastric emptying) but current UK guidance singles out tirzepatide specifically on this point. More on how this and other practical differences stack up is covered separately. If you're on HRT, NHS England also advises considering a transdermal option (patch or gel) over oral tablets while taking tirzepatide; it's a conversation worth having with your GP or our prescribers.

For anyone on Mounjaro who hasn't reviewed their contraception recently, this is genuinely worth a quick check before the next dose. It's one of those things that's easy to miss and easy to fix.

What this means for the decision in front of you

Both medicines come with a real GI adjustment period, especially in the first few weeks and after each step up in dose. For most people that settles. The data does not firmly establish that one medicine is universally "easier" than the other, individual response varies too much for that to be a reliable guide.

What does make a difference: how your prescriber titrates the dose, whether you're eating smaller, lower-fat meals during the adjustment phase, staying well hydrated, and not rushing through the escalation schedule. These are the levers that people who do well on these medicines tend to use.

If you've already tried one medicine and the side effects were unmanageable, that is useful clinical information. A prescriber may consider whether a switch makes sense, or whether adjusting the titration schedule on the same medicine is a better first step. The question of whether Wegovy really does cause fewer side effects gets into that nuance further.

You can also look at how the two treatments compare on cost if that's part of your thinking, and read more about the weight-loss treatment options nume offers. Our clinical team profile is at Mostafa Damghani's page if you want to know who reviews your consultation.

Which medicine is right for you is a clinical decision made with a prescriber who knows your full picture. Start your free consultation and a GPhC-registered prescriber will review it the same day.